Now that everyone has gotten over the initial news of the Vioxx recall, some of the more interesting analysis emerges.
The San Francisco Chronicle details how understaffed the FDA is:
Miceli said the FDA is woefully understaffed. And its guidelines often lead it to look only at the evidence presented by drug manufacturers, he said — not at the further data that could have been generated.
In the trial that was halted, 15 out of 1,000 patients taking Vioxx had heart attacks at three years–compared with 7.5 out of 1,000 for those taking only a sugar pill.